A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) as First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer

Publisher： Karger

E-ISSN： 1421-9794|54|3|228-235

ISSN： 0009-3157

Source： Chemotherapy, Vol.54, Iss.3, 2008-06, pp. : 228-235

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Retrospective Study of the Safety and Efficacy of a First-Line Treatment with Modified FOLFOX-4 in Unresectable Advanced or Recurrent Gastric Cancer Patients

By  

Chemotherapy, Vol. 58, Iss. 5, 2013-01 ,pp. : 411-418

Karger

Access to resources Recommend Favorite

A Phase II Study of Capecitabine plus Oxaliplatin as First-Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer

By  

Chemotherapy, Vol. 58, Iss. 1, 2012-02 ,pp. : 1-7

Karger

Access to resources Recommend Favorite

Oxaliplatin Combined with Continuous Infusion of 5-Fluorouracil as First-Line Chemotherapy in Patients with Metastatic or Recurrent Gastric Adenocarcinoma

By  

Chemotherapy, Vol. 55, Iss. 4, 2009-05 ,pp. : 200-206

Karger

Access to resources Recommend Favorite

Comparison of Cisplatin-5-Fluorouracil-Folinic Acid versus Modified Docetaxel-Cisplatin-5-Fluorouracil Regimens in the First-Line Treatment of Metastatic Gastric Cancer

By  

Chemotherapy, Vol. 57, Iss. 3, 2011-05 ,pp. : 230-235

Karger

Access to resources Recommend Favorite

HLA-G 3′UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer

By Garziera Marica   Virdone Saverio   De Mattia Elena   Scarabel Lucia   Cecchin Erika   Polesel Jerry   D’Andrea Mario   Pella Nicoletta   Buonadonna Angela   Favaretto Adolfo   Toffoli Giuseppe  

International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-06 ,pp. : 1366-1366

MDPI

Access to resources Recommend Favorite